When to start tapering off a GLP-1: clinician decision framework (2026)

The framing question: why are you stopping?

The reason for stopping a GLP-1 changes the protocol meaningfully. The four main reasons clinicians see, and how each shapes the taper decision:

Reason 1 — weight goal achieved and patient wants to discontinue. This is the elective taper scenario where a structured plan makes the most sense. Most clinical evidence on tapering comes from this context.

Reason 2 — intolerable side effects despite dose adjustment. Taper here is often abrupt — the side effects are the driving factor, not a planned protocol. Lower-dose maintenance may be an alternative to full discontinuation.

Reason 3 — cost or supply disruption. Often abrupt and not chosen by the patient. The clinical question becomes how to minimize rebound when discontinuation isn't optional.

Reason 4 — pregnancy planning or contraindication development. Discontinuation here is required, not optional. The taper protocol is focused on minimizing metabolic disruption during the period when GLP-1 is unavailable.

What the data shows on regain

The STEP-1 extension trial randomized participants who had completed 68 weeks of semaglutide 2.4 mg to either continue or switch to placebo for an additional year. Participants who switched to placebo regained approximately two-thirds of the weight lost during the active treatment phase over the subsequent 12 months. Participants who continued semaglutide maintained their weight loss.

Tirzepatide data from SURMOUNT-4 showed a similar pattern: after a 36-week tirzepatide lead-in, randomization to placebo led to weight regain of approximately 14% of body weight over 52 weeks, while continuation maintained weight loss.

These data suggest that for many patients, GLP-1s function more like blood-pressure medication than like an antibiotic — they treat an ongoing physiologic state rather than curing a transient condition. This shapes the taper conversation: the goal isn't necessarily to come off the drug, but to find the lowest effective maintenance dose.

When elective taper is reasonable to consider

Patient has been at goal weight for at least 12 months on a stable dose. Shorter maintenance periods don't appear in trial data to predict successful taper.

Patient is willing to commit to active weight monitoring (weekly or biweekly weights) and willing to resume treatment if regain crosses 10-15% of body weight.

Patient does NOT have an indication requiring ongoing therapy. Established cardiovascular disease on Wegovy is a meaningful consideration — the CV indication is independent of weight maintenance. Type 2 diabetes patients on semaglutide for glycemic control face similar reasoning.

Patient has actively maintained the behavioral changes that supported weight loss — protein-forward eating, regular movement, sleep regularity. Patients who relied entirely on the medication for behavioral effects (appetite suppression) without underlying habit change have higher rebound risk.

The taper protocol

Step 1 — drop one dose level every 4-8 weeks. For Wegovy, that means moving from 2.4 mg to 1.7 mg, then 1.0 mg, then 0.5 mg, then 0.25 mg, then off. Each step gives 4-8 weeks of observation to detect early regain before progressing.

Step 2 — establish baseline weight tracking before starting. Weekly morning weights, recorded in a simple log. The first 4-6 weeks of any step are the highest-risk window for regain detection.

Step 3 — define resumption threshold in advance. The conventional threshold is 10-15% of body weight regained from the maintenance baseline. Patient and clinician agree on this in advance to avoid emotional decision-making during regain.

Step 4 — at each step, evaluate not just weight but also pre-treatment symptoms. If hypertension, sleep apnea, or joint pain that resolved during treatment begins returning during taper, that's a signal to pause or reverse.

Step 5 — if a step is going well at 6-8 weeks (stable weight, no symptom return), proceed to next step. If weight is creeping up or symptoms returning, pause at the current dose for an additional 4-8 weeks before reassessing.

Maintenance dose alternative to full discontinuation

For many patients, the realistic outcome of a taper attempt is identifying a lower-dose maintenance regimen rather than full discontinuation. Some patients maintain weight loss on Wegovy 0.5 mg or 1.0 mg weekly — half or less of the maximum dose used in the active loss phase.

Lower-dose maintenance has practical advantages: lower cost (sometimes covered at lower formulary tiers), milder side-effect profile (GI symptoms typically dose-dependent), and reduced injection frequency for those using off-label dosing schedules (every 10-14 days at low doses).

Framing the taper attempt as a search for the minimum effective dose rather than a binary on/off decision can produce better outcomes. The patient who tries a taper and lands on Wegovy 0.5 mg weekly has succeeded at finding maintenance therapy, even though they didn't fully discontinue.

Forced discontinuation: when you don't have a choice

Supply disruptions, insurance changes, and job transitions can force abrupt discontinuation. The protocol differs from elective taper because optimization isn't possible — the goal is damage limitation.

Immediate steps when forced off: tighten behavioral structure — meal planning, scheduled eating windows, and pre-portioned meals reduce the appetite rebound that follows GLP-1 discontinuation. Increase protein intake to 1.4-1.6 g/kg to support satiety. Increase movement modestly to offset metabolic adaptation.

Plan resumption in advance. If the disruption is temporary (insurance lapse, supply gap), identify the resumption date and the protocol — most patients can resume at their maintenance dose without re-titration if the gap is under 6-8 weeks. Longer gaps may require restarting titration.